Compare Logitech International SA (LOGI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Spyre Therapeutics Inc. Common Stock — how do they compare? Logitech International SA trades at $101.81 (market cap $14.62B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Logitech International SA is the larger of the two by market cap, and Logitech International SA pays a 1.61% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LOGI | SYRE | |
|---|---|---|
Market Cap | $14.62B | $7.52B |
Volume | 811,529 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $126.69 | $108.92 |
52-Week Low | $85.84 | $22.18 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $12.95B | $6.52B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.16, up 2.88% today, with a bullish technical signal from moving averages and support at $101. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.85 beating expectations of $1.26. Fundamentals show robust profitability with a net margin of 16.28% and ROE of 35.29%, while recent news highlights new product launches and partnerships.
The outlook is positive with a consensus price target of $107, offering ~6% upside. Key opportunities include product innovation and market share gains, but risks involve chip shortages and competitive pressures. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid execution challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
